Free Trial

Nutex Health (NASDAQ:NUTX) Trading Down 8.9% - Should You Sell?

Nutex Health logo with Medical background
Image from MarketBeat Media, LLC.

Key Points

  • Shares fell 8.9% to $134.03 (previous close $147.17) on light trading of 34,665 shares—about an 83% drop versus average session volume.
  • The company beat EPS ($6.52 vs. $3.99 est.) but missed on revenue ($216.5M vs. $227.8M); Nutex trades at a P/E of ~10, market cap ≈ $900.8M, and sits above its 50- and 200-day moving averages.
  • Analysts have a consensus of "Moderate Buy" with an average price target of $252.50 despite recent downgrades, and institutional ownership is relatively low at about 5.32%.
  • MarketBeat previews top five stocks to own in June.

Nutex Health Inc. (NASDAQ:NUTX - Get Free Report)'s share price fell 8.9% during trading on Tuesday . The stock traded as low as $135.00 and last traded at $134.03. 34,665 shares were traded during mid-day trading, a decline of 83% from the average session volume of 199,959 shares. The stock had previously closed at $147.17.

Analyst Upgrades and Downgrades

NUTX has been the topic of a number of recent analyst reports. Weiss Ratings reiterated a "hold (c)" rating on shares of Nutex Health in a research report on Friday, March 27th. Wall Street Zen lowered Nutex Health from a "strong-buy" rating to a "hold" rating in a research report on Saturday, March 7th. Two research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, Nutex Health has an average rating of "Moderate Buy" and an average price target of $252.50.

Get Our Latest Stock Analysis on Nutex Health

Nutex Health Trading Down 12.2%

The company has a 50 day moving average of $102.21 and a 200 day moving average of $126.65. The company has a debt-to-equity ratio of 0.70, a quick ratio of 3.39 and a current ratio of 3.41. The stock has a market capitalization of $900.77 million, a price-to-earnings ratio of 9.99 and a beta of 0.25.

Nutex Health (NASDAQ:NUTX - Get Free Report) last posted its quarterly earnings data on Thursday, April 30th. The company reported $6.52 EPS for the quarter, beating the consensus estimate of $3.99 by $2.53. Nutex Health had a return on equity of 24.13% and a net margin of 10.95%.The firm had revenue of $216.49 million during the quarter, compared to the consensus estimate of $227.80 million.

Institutional Trading of Nutex Health

A number of hedge funds and other institutional investors have recently modified their holdings of NUTX. State of Alaska Department of Revenue acquired a new stake in shares of Nutex Health in the 3rd quarter worth $30,000. Islay Capital Management LLC acquired a new stake in shares of Nutex Health in the 4th quarter worth $34,000. BNP Paribas Financial Markets increased its stake in shares of Nutex Health by 966.7% in the 2nd quarter. BNP Paribas Financial Markets now owns 320 shares of the company's stock worth $40,000 after acquiring an additional 290 shares during the last quarter. Royal Bank of Canada increased its stake in shares of Nutex Health by 752.4% in the 4th quarter. Royal Bank of Canada now owns 358 shares of the company's stock worth $59,000 after acquiring an additional 316 shares during the last quarter. Finally, Bank of America Corp DE increased its stake in shares of Nutex Health by 6,590.3% in the 4th quarter. Bank of America Corp DE now owns 2,074 shares of the company's stock worth $66,000 after acquiring an additional 2,043 shares during the last quarter. 5.32% of the stock is owned by institutional investors and hedge funds.

Nutex Health Company Profile

(Get Free Report)

Nutex Health, Inc NASDAQ: NUTX is an integrated outpatient healthcare services company based in San Antonio, Texas. The company focuses on delivering a range of ambulatory care solutions, including urgent care, telemedicine, medical imaging, teleradiology, weight‐loss services and behavioral health support. By combining in‐person clinics with virtual care capabilities, Nutex Health aims to provide patients with accessible, cost‐effective treatment options outside traditional hospital settings.

The company’s urgent care network operates through both standalone and retail‐anchored centers, offering treatment for non‐life‐threatening injuries and illnesses, preventive screenings and basic primary care.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Nutex Health Right Now?

Before you consider Nutex Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nutex Health wasn't on the list.

While Nutex Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines